EKF Diagnostics Holdings PLC Notice of Results and Investor Presentation (3991R)
01 3월 2023 - 4:00PM
UK Regulatory
TIDMEKF
RNS Number : 3991R
EKF Diagnostics Holdings PLC
01 March 2023
EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Notice of Preliminary Results and Investor Presentation
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed
point-of-care business , will announce its preliminary results for
the year ended 31 December 2022, on Tuesday 28 March 2023.
Investor Presentation
Julian Baines, Executive Chair, and Marc Davies, Chief Financial
Officer, will be hosting a live online presentation relating to the
preliminary results via the Investor Meet Company platform at 4.30
pm on Tuesday 28 March 2023. The presentation is open to all
existing and potential shareholders.
Investors can sign up to Investor Meet Company for free and
register for the presentation here:
https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor
Investors who already follow EKF on the Investor Meet Company
platform will automatically be invited.
A recording of the presentation, a PDF of the slides used, and
responses to the Q&A session will be available on the Investor
Meet Company platform afterwards.
EKF Diagnostics Holdings plc www.ekfdiagnostics.com
Julian Baines, Executive Chair / Marc Tel: +44 (0)29 2071 0570
Davies, CFO
Singer Capital Markets (Nominated Adviser & Tel: + 44 ( 0)20 7496 3000
Joint Broker)
Aubrey Powell / George Tzimas / Oliver
Platts
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Paul McManus / Lianne Applegarth Mob: +44 (0)7980 541 893 / +44 (0)7584 391
303
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com
)
EKF is a leading global diagnostics business with custom
manufacturing facilities across sites in the US, UK and Europe for
a variety of life science products. EKF is focussed on the
following areas:
Point-of-Care Providing a portfolio of Point-of-Care analysers
and consumables, particularly for use in the area
of Hematology and Diabetes, for use in hospital and
research laboratories, doctor's offices, blood banks
and for in-field anaemia screening programmes. EKF
has an estimated 80,000 hemoglobin, hematocrit, HbA1c,
glucose and lactate analysers in regular use across
more than 100 countries.
Central Laboratory Clinical chemistry, Small lab analysers, Centrifuges
Beta-Hydroxybutyrate (<BETA>-HB) LiquiColor , Glycated
Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
Life Sciences Enzyme fermentation, Custom products and Bulk fermentation
Contract Manufacturing Bulk formulation, Sample collection kits, Private
labelling, Molecular and forensic kits
Laboratory Testing Laboratory testing services certified under the Clinical
Laboratory Improvement Amendments ("CLIA") for high
complexity testing.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORSELFWAEDSEFE
(END) Dow Jones Newswires
March 01, 2023 02:00 ET (07:00 GMT)
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 11월(11) 2024 으로 12월(12) 2024
EKF Diagnostics (AQSE:EKF.GB)
과거 데이터 주식 차트
부터 12월(12) 2023 으로 12월(12) 2024
